- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- Faster-acting insulin aspart, Insulin aspart, Insulin degludec, Metformin
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 64
- States / cities
- Concord, California • Fresno, California • Fullerton, California + 56 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 793–816
of 1,115
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Carvedilol, Laboratory Biomarker Analysis, Patient Observation
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 491 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2031
- U.S. locations
- 577
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Hot Springs, Arkansas + 375 more
- Conditions
- Arrhythmia, Bradycardia
- Interventions
- Pacemaker
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- Not listed
- Enrollment
- 860 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 51
- States / cities
- Anchorage, Alabama • Mobile, Alabama • Fullerton, California + 48 more
- Conditions
- Atherosclerosis
- Interventions
- Canakinumab, Placebo, Standard of care
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,066 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 315
- States / cities
- Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 248 more
- Conditions
- Acute Myeloid Leukemia (AML) With, FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)
- Interventions
- Midostaurin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Berkeley, California • Duarte, California + 35 more
- Conditions
- Liver Neoplasms, Primary Liver Cancer, Secondary Liver Cancer, Tumor Liver, Benign Liver Tumor
- Interventions
- HistoSonics Edison System
- Device
- Lead sponsor
- HistoSonics, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2039
- U.S. locations
- 33
- States / cities
- Fullerton, California • Los Angeles, California • Mission Viejo, California + 26 more
- Conditions
- Head and Neck Cancer
- Interventions
- Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Fullerton, California • Long Beach, California + 12 more
- Conditions
- Parkinson Disease Psychosis
- Interventions
- Pimavanserin
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Fullerton, California • Miami, Florida + 15 more
- Conditions
- Acne Vulgaris
- Interventions
- Dapsone 5.0% Gel (SEEGPharm), Placebo, Dapsone 5.0% Gel (Allergan)
- Drug · Other
- Lead sponsor
- Seegpharm S.A.
- Industry
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 2,361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 35
- States / cities
- Encino, California • Fullerton, California • La Mesa, California + 29 more
- Conditions
- Alzheimer's Disease
- Interventions
- T-817MA-H, T-817MA-L, Placebo
- Drug
- Lead sponsor
- FUJIFILM Toyama Chemical Co., Ltd.
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 46 more
- Conditions
- Multiple Sclerosis
- Interventions
- ofatumumab with PRF, ofatumumab with AI
- Combination Product
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 13
- States / cities
- Fullerton, California • Aurora, Colorado • Basalt, Colorado + 9 more
- Conditions
- Cancer
- Interventions
- Talazoparib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 26
- States / cities
- Alhambra, California • Bakersfield, California • Burbank, California + 16 more
- Conditions
- Coronavirus Disease (COVID-19)
- Interventions
- Molnupiravir, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,441 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 53 more
- Conditions
- Allergic Conjunctivitis
- Interventions
- bepotastine besilate, 1.5%, Loteprednol etabonate
- Drug
- Lead sponsor
- Southern California College of Optometry at Marshall B. Ketchum University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Fullerton, California
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Intismeran autogene, Placebo
- Biological · Drug · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2038
- U.S. locations
- 54
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Fullerton, California + 42 more
- Conditions
- Alzheimer Disease
- Interventions
- TRx0237 16 mg/day, Control, TRx0237 8 mg/day
- Drug
- Lead sponsor
- TauRx Therapeutics Ltd
- Industry
- Eligibility
- Up to 90 Years
- Enrollment
- 598 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 44 more
- Conditions
- Colorectal Cancer
- Interventions
- Capecitabine, Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,886 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 48
- States / cities
- Mobile, Alabama • Alhambra, California • Bakersfield, California + 43 more
- Conditions
- Asthma
- Interventions
- GP MDI 28.8 μg, GP MDI 14.4 μg, GP MDI 7.2 μg, Placebo MDI, Spiriva Respimat 2.5 μg
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 1,077 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 232
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 188 more
- Conditions
- Metastatic Cancer, Epithelial Tumor
- Interventions
- NG-641 in combination with Nivolumab
- Biological
- Lead sponsor
- Akamis Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Fullerton, California • Santa Monica, California • Celebration, Florida + 1 more
- Conditions
- Macular Degeneration
- Interventions
- Abicipar pegol
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 32 more
- Conditions
- Breast Cancer
- Interventions
- trastuzumab, carboplatin, docetaxel, lapatinib ditosylate
- Biological · Drug
- Lead sponsor
- Translational Oncology Research International
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 15
- States / cities
- Alhambra, California • Bakersfield, California • Fullerton, California + 10 more
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- EYP-1901, Aflibercept 2mg/0.05mL Inj,Oph
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 67
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Beverly Hills, California + 64 more
- Conditions
- Overweight, Obesity, Type 2 Diabetes Mellitus
- Interventions
- Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 49
- States / cities
- Concord, California • Escondido, California • Fullerton, California + 39 more
- Conditions
- Cervical Cancer
- Interventions
- Intervention
- Behavioral
- Lead sponsor
- California State University, Fullerton
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 1,014 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Fullerton, California